ArticleInternational journal of molecular sciences2026
Bridging E3 Ligase Binding and Targeted Degradation Through Fluorescence Polarization.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Despite the rapid expansion of targeted protein degradation (TPD), early characterization of PROTACs and molecular glues still relies predominantly on cellular degradation assays, making it difficult to determine whether poor degradation results from suboptimal E3 ligase engagement or from subsequent steps in the degradation mechanism. Moreover, productive degradation depends on balanced binary interactions, as both insufficient and excessively strong binding to either the E3 ligase or the protein of interest (POI) can impair degrader activity. Here, we report robust fluorescence polarization (FP) assays for the quantitative determination of ligand binding to the two most widely exploited E3 ligases, cereblon (CRBN) and von Hippel-Lindau (VHL). Using proprietary fluorescent tracers, the assays were validated with chemically diverse molecular glues, clinically relevant PROTACs, and canonical ligands, yielding affinity values in excellent agreement with published data. Both assays were successfully miniaturized to 384-well format while maintaining analytical performance and subsequently implemented in standardized ready-to-use formats, facilitating reproducible affinity measurements across laboratories. These assays establish a rapid and accessible binding-first platform that complements cellular degradation studies; supports rational degrader discovery, profiling, and optimization; and enables the identification of structurally novel E3 ligase recruiters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.